Derm-Biome’s DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that its topical drug DB-007-5 was highly effective at treating atopic dermatitis (AD) and is more potent at reducing itch than the current leading AD drug in a […]